1
|
Iida Y, Osaki M, Sato S, Izutsu R, Seong H, Okawa M, Osaku D, Komatsu H, Taniguchi F, Okada F. AMIGO2 expression as a predictor of recurrence in cervical cancer with intermediate risk. Mol Clin Oncol 2023; 19:56. [PMID: 37323247 PMCID: PMC10265584 DOI: 10.3892/mco.2023.2652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 03/16/2023] [Indexed: 06/17/2023] Open
Abstract
Patients with recurrent cervical cancer have limited treatment options and are often considered to be incurable. Since the expression of amphoterin-induced gene and open reading frame 2 (AMIGO2) in clinical samples is a prognostic factor for colorectal cancer and gastric cancer, the present aimed to elucidate whether it is also a prognostic factor for cervical cancer. Patients with primary cervical cancer who underwent radical hysterectomy or radical trachelectomy at our institution (Faculty of Medicine, Tottori University, Yonago, Japan) between September 2005 and October 2016 were retrospectively collected. Immunohistochemical analysis using a specific antibody against AMIGO2 was performed on 101 tumor samples, and the clinical characteristics, disease-free survival (DFS) and overall survival (OS) of the patients were examined. Patients in the AMIGO2-high group had a shorter 5-year DFS and OS than those in the AMIGO2-low group (P<0.001). Furthermore, AMIGO2 was an independent prognostic factor for DFS in multivariate analysis (P=0.0012). Patients in the AMIGO2-high group exhibited obvious recurrence compared with those in the AMIGO2-low group in the high-(P=0.03) and intermediate-risk groups (P=0.003). Positive lymph node metastasis, and parametrial, stromal and lymph vascular space invasion were significantly more common in AMIGO2-high patients. Taken together, AMIGO2 expression may be a predictive marker of recurrence for cervical cancer. In particular, it may be an indicator to determine the need for postoperative adjuvant therapy in intermediate-risk group patients.
Collapse
Affiliation(s)
- Yuki Iida
- Division of Experimental Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Mitsuhiko Osaki
- Division of Experimental Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
- Chromosome Engineering Research Center, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Shinya Sato
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Runa Izutsu
- Division of Experimental Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Heekyung Seong
- Division of Experimental Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Masayo Okawa
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Daiken Osaku
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Hiroaki Komatsu
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Fuminori Taniguchi
- Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Futoshi Okada
- Division of Experimental Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
- Chromosome Engineering Research Center, Tottori University, Yonago, Tottori 683-8503, Japan
| |
Collapse
|
2
|
Ishizawa C, Taguchi A, Tanikawa M, Honjo H, Nishijima A, Eguchi S, Miyamoto Y, Sone K, Tsuruga T, Mori M, Osuga Y. Effect of pelvic radiotherapy on patients with stage IB‑IIA cervical cancer after radical hysterectomy: A single‑center retrospective study. Oncol Lett 2023; 25:112. [PMID: 36817060 PMCID: PMC9932628 DOI: 10.3892/ol.2023.13698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 12/19/2022] [Indexed: 02/05/2023] Open
Abstract
The effects of post-operative adjuvant radiotherapy (RT) on intermediate-risk patients with cervical cancer have not been fully elucidated. Therefore, the present study aimed to investigate the impact of RT on intermediate-risk cervical cancer. The data of 112 patients with stage IB and IIA cervical cancer treated with radical hysterectomy between January 2009 and December 2018 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the frequency of adverse events were compared between patients with and without adjuvant RT (RT+ and RT-, respectively). Subgroup analyses of PFS based on tumor size, cervical stromal invasion, lymphovascular space invasion and histology [squamous cell carcinoma (SCC) vs. non-SCC] were performed. Among the 112 patients, 41 received adjuvant RT. Although there were no significant differences in OS or PFS between the RT+ and RT- groups, the frequency of adverse events was much higher in the RT+ group. Patients in the RT+ group also had more recurrent risk factors than those in the RT- group. Based on the subgroup analyses, although no significant differences were observed between any of the groups, RT demonstrated a different impact on PFS between SCC and non-SCC: No difference was observed in the SCC group, whereas patients in the RT+ group tended to have poorer prognoses compared to those in the RT- group of the non-SCC group. These results suggest that the impact of post-operative RT on stage IB and IIA cervical cancer is limited and is accompanied by increased adverse events. The eligibility of patients for post-operative RT should be carefully determined based on the therapeutic effect of RT in each subgroup.
Collapse
Affiliation(s)
- Chihiro Ishizawa
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Ayumi Taguchi
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan,Correspondence to: Dr Ayumi Taguchi, Department of Obstetrics and Gynecology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan, E-mail:
| | - Michihiro Tanikawa
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Harunori Honjo
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Akira Nishijima
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Satoko Eguchi
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Yuichiro Miyamoto
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Kenbun Sone
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Tetsushi Tsuruga
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Mayuyo Mori
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Yutaka Osuga
- Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| |
Collapse
|